HMS Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

HMS Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-497	Closed	-$222K	–	123
2026 Q1	$222K	Hold	497	–	–	0.09%	110
2025 Q4	$225K	Sell	497 -448	-47%	-$193K	0.09%	100
2025 Q3	$370K	Sell	945 -3	-0.3%	-$1.25K	0.16%	86
2025 Q2	$422K	Sell	948 -122	-11%	-$56.2K	0.19%	83
2025 Q1	$508K	Buy	1,070 +473	+79%	+$220K	0.28%	63
2024 Q4	$240K	Hold	597	–	–	0.12%	102
2024 Q3	$278K	Hold	597	–	–	0.14%	97
2024 Q2	$280K	Hold	597	–	–	0.15%	94
2024 Q1	$250K	Hold	597	–	–	0.14%	98
2023 Q4	$243K	Hold	597	–	–	0.15%	96
2023 Q3	$208K	Hold	597	–	–	0.14%	106
2023 Q2	$210K	Sell	597 -155	-21%	-$52.2K	0.13%	108
2023 Q1	$237K	Hold	752	–	–	0.15%	102
2022 Q4	$217K	Sell	752 -20	-3%	-$6.09K	0.12%	93
2022 Q3	$224K	Hold	772	–	–	0.14%	110
2022 Q2	$218K	Buy	+772	New	+$207K	0.11%	115
2021 Q3	–	Sell	-1,270	Closed	-$256K	–	137
2021 Q2	$256K	Hold	1,270	–	–	0.12%	118
2021 Q1	$273K	Hold	1,270	–	–	0.12%	109
2020 Q4	$300K	Sell	1,270 -4,294	-77%	-$985K	0.14%	115
2020 Q3	$1.51M	Sell	5,564 -326	-6%	-$89.9K	0.59%	34
2020 Q2	$1.71M	Buy	5,890 +4,888	+488%	+$1.33M	0.75%	27
2020 Q1	$238K	Hold	1,002	–	–	0.23%	73
2019 Q4	$219K	Buy	+1,002	New	+$203K	0.09%	146
2019 Q3	–	Sell	-1,002	Closed	-$184K	–	291
2019 Q2	$184K	Buy	+1,002	New	+$175K	0.08%	149
2019 Q1	–	Sell	-2,482	Closed	-$411K	–	210
2018 Q4	$411K	Hold	2,482	–	–	0.21%	120
2018 Q3	$478K	Hold	2,482	–	–	0.24%	133
2018 Q2	$422K	Buy	+2,482	New	+$385K	0.24%	120

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

HMS Capital Management's VRTX Position: Q2 2026 in Review

HMS Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 497 shares — an estimated $222K sold.

HMS Capital Management first reported a position in VRTX in Q2 2018 and held it in 27 quarters. The position peaked at $1.71M in Q2 2020. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

HMS Capital Management reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
HMS Capital Management sold 497 Vertex Pharmaceuticals shares in Q2 2026, an estimated $222K.
HMS Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2018 and held it in 27 quarters.
HMS Capital Management's Vertex Pharmaceuticals position peaked at $1.71M in Q2 2020.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on HMS Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.